BamSEC and AlphaSense Join Forces
Learn More

Allogene Therapeutics Inc. – Material Contracts

NASDAQ: ALLO    
Share price (11/4/26): $1.19    
Market cap (11/4/26): $411 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.5
from 10-Q 2 pages First Amendment To
12/34/56
EX-10.4
from 10-Q 37 pages May 28, 2026 Dr. Zachary Roberts Re: Employment Letter of Agreement (“Agreement”) Dear Zach: Allogene Therapeutics, Inc. (“Allogene” or the “Company”) Is Pleased to Offer You Continued Employment on the Following Terms and Conditions. 1. Title; Reporting; Duties
12/34/56
EX-10.2
from 10-Q 34 pages Second Amended and Restated Shareholders’ Agreement
12/34/56
EX-10.1
from 10-Q 6 pages Termination Agreement
12/34/56
EX-10.6
from 10-Q 21 pages Allogene Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.6
from 10-Q 20 pages Allogene Therapeutics, Inc. Consulting Agreement
12/34/56
EX-10.5
from 10-Q 12 pages Allogene Therapeutics, Inc. Restricted Stock Unit Grant Notice
12/34/56
EX-10.4
from 10-Q 47 pages Amended and Restated Strategic Collaboration Agreement Between Foresight Diagnostics, Inc. and Allogene Therapeutics, Inc. Dated as of January 3, 2024
12/34/56
EX-10.1
from 10-Q 4 pages Allogene Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: Adopted: September 26, 2018 Amended: April 16, 2019 Amended: September 17, 2019 Amended: September 13, 2023 Amended: March 28, 2024 Amended: March 12, 2025 Amended: April 11, 2025
12/34/56
EX-10.13
from 10-K 132 pages Exclusive License and Collaboration Agreement Between Les Laboratoires Servier Sas Institut De Recherches Internationales Servier Sas and Pfizer Inc
12/34/56
EX-10.7
from 10-Q 2 pages Amendment 1 to Strategic Collaboration Agreement
12/34/56
EX-10.6
from 10-Q 3 pages Agreement
12/34/56
EX-10.4
from 10-Q 23 pages Amendment and Settlement Agreement
12/34/56
EX-10.3
from 10-Q 9 pages First Amendment to Exclusive License Agreement
12/34/56
EX-10.2
from 10-Q 37 pages Amended and Restated Shareholders’ Agreement
12/34/56
EX-10.1
from 10-Q 43 pages Share Exchange Agreement
12/34/56
EX-10.1
from 8-K 13 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Allogene Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: September 26, 2018 Amended: April 16, 2019 Amended: September 17, 2019 Amended: September 13, 2023 Amended: March 28, 2024
12/34/56
EX-10.30
from 10-K 38 pages Strategic Collaboration Agreement Between Foresight Diagnostics, Inc. and Allogene Therapeutics, Inc. Dated as of January 3, 2024 Strategic Collaboration Agreement
12/34/56
EX-10.18
from 10-K 46 pages Amended and Restated Collaboration and License Agreement
12/34/56